-
Analyst: AveXis M&A Could Support Interest In Regenxbio
Monday, April 9, 2018 - 1:36pm | 408Regenxbio Inc (NASDAQ: RGNX) rode a tailwind Monday from the announced acquisition of its partner AveXis Inc (NASDAQ: AVXS), and the benefits may keep coming. The Rating Chardan analyst Gbola Amusa reiterated a Buy rating on Regenxbio and increased the price target from $85 to $90. The...